UNICREDIT BANK/CALL/BIOGEN IDEC/320/0.1/18.06.25 | Market Closed - BOERSE MUENCHEN 20:40:30 31/05/2024 BST | ||
| 1.19 EUR | +12.26% |
|
| 1 month | +43.37% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 1.19 | +12.26% |
| 30/05/24 | 1.06 | +8.16% |
| 29/05/24 | 0.98 | -5.77% |
| 28/05/24 | 1.04 | -2.80% |
| 27/05/24 | 1.07 | -.--% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 08:40 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD4WFP |
| ISIN | DE000HD4WFP0 |
| Date issued | 22/04/2024 |
| Strike | 320 $ |
| Maturity | 18/06/2025 (382 Days) |
| Parity | 10 : 1 |
| Emission price | 0.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.46 € |
|---|---|
| Lowest since issue | 0.51 € |
| Spread | 0.02 € |
| Spread % | 1.65% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
224.9
USD
Average target price
284.8
USD
Spread / Average Target
+26.60%
- Stock Market
- Warrants
- Warrant
